Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
Robert D MorganAndrew R ClampDaniel J WhiteMarcus PriceGeorge Joseph BurghelW David J RyderReem D MahmoodAlexander D MurphyJurjees HasanClaire L MitchellZena SalihChelsey WheelerEmma BuckleyJoanna TrueloveGeorgia KingYasmina AinaouiSanjeev S BhaskarJoseph ShawDafydd Gareth EvansBedirhan KilerciSimon P PearceGed BradyCaroline DiveJames P B O'ConnorAndrew J WallaceDominic G RothwellRichard John EdmondsonGordon C JaysonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
A second course of olaparib can be safely administered to women with gBRCAm-HGSOC but is only modestly efficacious.